Hormonal therapy continues to be the cure of first choice for metastatic patients with endocrine-responsive breast most cancers (LoE 1a A, In the past ++). The sequential use with the accessible medications depends on the individual pretreatment. Reassessment of ER, PR, and HER2 in tumor tissue at enough time https://frankf219hrd0.wikistatement.com/user